NASDAQ:MENS

Jyong Biotech Q4 2025 Earnings Results & Report

Jyong Biotech logo
$1.80 +0.03 (+1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 +0.02 (+1.11%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jyong Biotech reported Q4 2025 earnings on May 15, 2026. The company reported EPS of -$0.02.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Jyong Biotech EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Jyong Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Jyong Biotech Q4 2025 Earnings FAQ

Jyong Biotech (NASDAQ:MENS) reported earnings of -$0.02 per share for Q4 2025. The report was announced on Friday, May 15, 2026.

Jyong Biotech Earnings Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
See More Jyong Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jyong Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jyong Biotech and other key companies, straight to your email.

About Jyong Biotech

Jyong Biotech (NASDAQ:MENS) is a clinical-stage biopharmaceutical company based in Taiwan that develops treatments for urological diseases. Its research focuses on botanical drug candidates, including therapies for conditions affecting the prostate and urinary system.

The company’s pipeline includes MCS-2, a botanical drug candidate being developed for benign prostatic hyperplasia, a noncancerous enlargement of the prostate. Jyong Biotech is also developing other candidates for urological conditions.

Jyong Biotech was established in Taiwan and conducts drug development activities there. Its focus is on advancing its pipeline through clinical development; its candidates are investigational and are not established treatments.

View Jyong Biotech Profile